In human prostatic secretions, the protein content is less than 1% and includes proteolytic enzymes, prostatic acid phosphatase, and prostate-specific antigen. The secretions also contain zinc with a concentration 500-1,000 times the concentration in blood.
The main male hormone is testosterone, which is produced mainly by the testicles. Some male hormones are produced in small amounts by the adrenal glands. However, it is dihydrotestosterone that regulates the prostate.
The ducts are lined with transitional epithelium.
Within the prostate, the urethra coming from the bladder is called the prostatic urethra and merges with the two ejaculatory ducts. (The male urethra has two functions: to carry urine from the bladder during urination and to carry semen during ejaculation.) The prostate is sheathed in the muscles of the pelvic floor, which contract during the ejaculatory process.
The prostate can be divided in two different ways: by zone, or by lobe.
The prostate gland has four distinct glandular regions, two of which arise from different segments of the prostatic urethra:
|Peripheral zone (PZ)||Composes up to 70% of the normal prostate gland in young men||The sub-capsular portion of the posterior aspect of the prostate gland which surrounds the distal urethra. It is from this portion of the gland that more than 64% of prostatic cancers originate.|
|Central zone (CZ)||Constitutes approximately 25% of the normal prostate gland||This zone surrounds the ejaculatory ducts. The central zone accounts for roughly 2.5% of prostate cancers although these cancers tend to be more aggressive and more likely to invade the seminal vesicles.|
|Transition zone (TZ)||Responsible for 5% of the prostate volume at puberty.||Prostate cancer originates in this zone in roughly 34% of patients. The transition zone surrounds the proximal urethra and is the region of the prostate gland which grows throughout life and is responsible for the disease of benign prostatic enlargement. (2)|
|Anterior fibro-muscular zone (or stroma)||Accounts for approximately 5% of the prostatic weight||This zone is usually devoid of glandular components, and composed only, as its name suggests, of muscle and fibrous tissue.|
The "lobe" classification is more often used in anatomy.
|Anterior lobe (or isthmus)||roughly corresponds to part of transitional zone|
|Posterior lobe||roughly corresponds to peripheral zone|
|Lateral lobes||spans all zones|
|Median lobe (or middle lobe)||roughly corresponds to part of central zone|
BPH can be treated with medication, a minimally invasive procedure or, in extreme cases, surgery that removes the prostate. Minimally invasive procedures include Transurethral needle ablation of the prostate (TUNA) and Transurethral microwave thermotherapy (TUMT). These outpatient procedures may be followed by the insertion of a temporary Prostatic stent, to allow normal voluntary urination, without exacerbating irritative symptoms.
The surgery most often used in such cases is called transurethral resection of the prostate (TURP or TUR). In TURP, an instrument is inserted through the urethra to remove prostate tissue that is pressing against the upper part of the urethra and restricting the flow of urine. Older men often have corpora amylacea (amyloid), dense accumulations of calcified proteinaceous material, in the ducts of their prostates. The corpora amylacea may obstruct the lumens of the prostatic ducts, and may underlie some cases of BPH.
Urinary frequency due to bladder spasm, common in older men, may be confused with prostatic hyperplasia. Statistical observations suggest that a diet low in fat and red meat and high in protein and vegetables, as well as regular alcohol consumption, could protect against BPH.
Though prostate cancer is of most concern to older men, it is like other cancers, a complex disease with many risk factors; race, age, genetics, and lifestyle habits can all contribute to its development.
However, in March of the same year, the National Institute of Child Health and Human Development held a conference cosponsored by the National Cancer Institute and others to review the available data and information on the link between prostate cancer and vasectomies. It was determined that an association between the two was very weak at best, and even if having a vasectomy increased one's risk, the risk was relatively small.
In 1997, the NCI held a conference with the prostate cancer Progressive Review Group (a committee of scientists, medical personnel, and others). Their final report, published in 1998 stated that evidence that vasectomies help to develop prostate cancer was weak at best.
HRT linked to increase in urinary incontinence risk: but other research suggests estrogen may protect against irritative symptoms. (Symptoms in 7% on Estrogen, 1% on Placebo).
Nov 15, 2001; NEW ORLEANS -- Increasing evidence suggests that hormone replacement therapy, once thought to be protective against urinary...
Wipo Publishes Patent of Taris Biomedical, Himes Julie, Giesing Dennis, Larriveee-Elkins Cheryl, Cima Michael J., Sarma Purnanand, Goldenheim Paul for "Lidocaine Regimen for the Use of Sustained Treatment of Bladder Pain and Irritative Voiding" (American Inventors)
Aug 06, 2012; GENEVA, Aug. 6 -- Publication No. WO/2012/096985 was published on July 19. Title of the invention: "LIDOCAINE REGIMEN FOR THE USE...
Wipo Publishes Patent of Yonsei University Industry-Academic Cooperation Foundation and Huons for "Cyclosporine-Containing, Non-Irritative Nanoemulsion Opthalmic Composition" (South Korean Inventors)
Nov 08, 2013; GENEVA, Nov. 8 -- Publication No. WO/2013/165074 was published on Nov. 7.Title of the invention: "CYCLOSPORINE-CONTAINING,...